Collaborators Work On Bionic Pancreas System

Senseonics Holdings, a med-tech company focused on the development and commercialization of transformative glucose monitoring products, and Beta Bionics, a med-tech leveraging machine learning artificial intelligence to develop and commercialize the first autonomous bionic pancreas, have entered into a development agreement to integrate glucose data from the Eversense Continuous Glucose Monitoring (CGM) system into the iLet Bionic Pancreas system. The Eversense CGM system is a long-term, implantable continuous glucose monitoring system that continually measures interstitial fluid glucose levels and wirelessly sends the readings to a smartphone application. The iLet Bionic Pancreas system is a dual-chamber, autonomous, infusion pump that mimics a biological pancreas by automatically and autonomously adapting insulin and glucagon dosing to meet the individual needs of a person with diabetes.

 

Under this development agreement, Beta Bionics will work with Senseonics to integrate the Eversense CGM system with the iLet, so that real-time Eversense data may serve as one CGM option to drive the fully autonomous iLet Bionic Pancreas system.

 

For more insights and better blood-sugar levels, visit Senseonics and Beta Bionics.